Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)

ADC ID	DRG0PSIFH
ADC Name	WO2022253035A1 ADC-32
Synonyms	WO2022253035A1 ADC 32 Click to Show/Hide
Organization	Sichuan Kelun Pharmaceutical Co., Ltd.
Drug Status	Investigative
Indication	In total 3 Indication(s) Colorectal cancer [ICD11:2B91] Investigative Gastric cancer [ICD11:2B72] Investigative Pancreatic cancer [ICD11:2C10] Investigative
Drug-to-Antibody Ratio	7.5
Structure
	3D MOL	2D MOL
Antibody Name	19F6_Hu35v1		Antibody Info
Antigen Name	Inactive tyrosine-protein kinase transmembrane receptor ROR1 (ROR1)		Antigen Info
Payload Name	Undisclosed
Linker Name	WO2022253035A1 ADC-32 linker

General Information of The Activity Data Related to This ADC

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Standard Type	Value	Units	Cell Line	Disease Model
Half Maximal Inhibitory Concentration (IC50)	13.5	ug/mL	NCI-H1975 cells	Lung adenocarcinoma
Half Maximal Inhibitory Concentration (IC50)	15.1	ug/mL	NCI-N87 cells	Gastric tubular adenocarcinoma

Full List of Activity Data of This Antibody-drug Conjugate

Revealed Based on the Cell Line Data

Click To Hide/Show 2 Activity Data Related to This Level

Experiment 1 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	13.50 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Lung adenocarcinoma	NCI-H1975 cells		CVCL_1511
Experiment 2 Reporting the Activity Date of This ADC					[1]
Efficacy Data	Half Maximal Inhibitory Concentration (IC50)	15.10 ug/mL	Positive ROR1 expression (ROR1 +++/++)
Method Description	Cells were plated at about 500 cells per well in a 96-well plate in 100 uL of media. In vitro activity and targeted delivery of ADCs, the isotype-matched negative controls ADCs, and naked antibodies control were assessed in cells.
In Vitro Model	Gastric tubular adenocarcinoma	NCI-N87 cells		CVCL_1603

References

Ref 1	Antibody drug conjugate, and preparation method therefor and use thereof; 2022-12-08.